Correlation Between Molecular Partners and Anebulo Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Molecular Partners and Anebulo Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and Anebulo Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Molecular Partners AG and Anebulo Pharmaceuticals, you can compare the effects of market volatilities on Molecular Partners and Anebulo Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of Anebulo Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and Anebulo Pharmaceuticals.
Diversification Opportunities for Molecular Partners and Anebulo Pharmaceuticals
-0.05 | Correlation Coefficient |
Good diversification
The 3 months correlation between Molecular and Anebulo is -0.05. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and Anebulo Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Anebulo Pharmaceuticals and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with Anebulo Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Anebulo Pharmaceuticals has no effect on the direction of Molecular Partners i.e., Molecular Partners and Anebulo Pharmaceuticals go up and down completely randomly.
Pair Corralation between Molecular Partners and Anebulo Pharmaceuticals
Given the investment horizon of 90 days Molecular Partners AG is expected to under-perform the Anebulo Pharmaceuticals. In addition to that, Molecular Partners is 1.32 times more volatile than Anebulo Pharmaceuticals. It trades about -0.07 of its total potential returns per unit of risk. Anebulo Pharmaceuticals is currently generating about 0.02 per unit of volatility. If you would invest 289.00 in Anebulo Pharmaceuticals on February 1, 2024 and sell it today you would earn a total of 1.00 from holding Anebulo Pharmaceuticals or generate 0.35% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Insignificant |
Accuracy | 100.0% |
Values | Daily Returns |
Molecular Partners AG vs. Anebulo Pharmaceuticals
Performance |
Timeline |
Molecular Partners |
Anebulo Pharmaceuticals |
Molecular Partners and Anebulo Pharmaceuticals Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Molecular Partners and Anebulo Pharmaceuticals
The main advantage of trading using opposite Molecular Partners and Anebulo Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, Anebulo Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Anebulo Pharmaceuticals will offset losses from the drop in Anebulo Pharmaceuticals' long position.Molecular Partners vs. Invesco Trust For | Molecular Partners vs. LSI Industries | Molecular Partners vs. American Funds 2025 | Molecular Partners vs. Merck Company |
Anebulo Pharmaceuticals vs. Adagene | Anebulo Pharmaceuticals vs. Acrivon Therapeutics Common | Anebulo Pharmaceuticals vs. AnaptysBio | Anebulo Pharmaceuticals vs. Mineralys Therapeutics Common |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Complementary Tools
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |